Table II.
IC50a | ||||||||
---|---|---|---|---|---|---|---|---|
|
||||||||
Exposure time (h) | II18 | RERF-LC-Ad1 | PC-14 | A549 | RERF-LC-Ad2 | Lu99B | RERF-LC-KJ | |
24 | −8.32 | −8.10 | −7.67 | −7.73 | −8.29 | −5.60 | −3.70 | |
xCELLigence® | 48 | −8.33 | −7.78 | −7.65 | −7.69 | −8.15 | −5.10 | −4.51 |
72 | −8.18 | −8.41 | −7.69 | −7.07 | −7.99 | −5.35 | −4.83 | |
WST-8b | 48 | −10.80 | −9.36 | −9.34 | −8.48 | −7.26 | −7.68 | −4.48 |
IC50, drug concentration (in logM) at which cell growth is inhibited by 50%;
WST-8, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium.